Nasdaq
$2.29▲ 2.23%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $36.8MShares out 16.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.8Pre-market26.09.08 21:178-KKey event#●●●#●●●
VERU INC.Bullish
Veru announced positive preclinical data showing that its oral drug, sabizabulin, demonstrates potent anticancer activity in daraxonrasib-resistant metastatic pancreatic cancer cell lines. Consequently, the company has decided to advance sabizabulin into a Phase 2b clinical trial for this indication and will discontinue its development for chronic inflammation related to atherosclerotic cardiovascular disease.…more
$2.29+2.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.17After-hours26.08.18 05:264Ownership
VERU INC.
VERU INC. insider BARNETTE K GARY filed a Form 4 report on August 13, 2026, regarding changes in beneficial ownership of securities. This filing serves as a standard regulatory disclosure of insider holdings and does not contain material events affecting the company's operations or financial position.…more
$2.29+2.23%vs prev closeView filingShare - 8.10Pre-market26.08.10 21:5110-QEarnings
VERU INC.
Veru Inc.는 2026년 6월 30일로 종료된 분기에 대한 10-Q 재무 보고서를 제출했습니다. 해당 공시는 회사의 재무 상태와 운영 결과를 포함하고 있으며, 최고경영자(CEO)와 최고재무책임자(CFO)가 재무제표의 정확성과 내부 통제 절차의 준수 여부를 공식 인증했습니다.…more
$2.29+2.23%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.8Pre-market26.09.08 21:17#●●●#●●●
Veru to Advance Sabizabulin to Phase 2 for Pancreatic Cancer
Veru plans to initiate a Phase 2 clinical trial for sabizabulin after preclinical data showed potential to overcome resistance to existing KRAS-driven pancreatic cancer therapies. However, as this remains in early development, the company's future success depends on clinical trial outcomes and potential additional funding.…more
$2.29+2.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.10Pre-market26.08.10 19:30
●●●●●●●● ●●●●● ●●●●●●
베루는 비만 치료제 후보물질 에노보삼의 임상 2b상 환자 등록을 완료하고 노보 노디스크와 공급 계약을 체결하는 등 임상 개발에 속도를 내고 있습니다. 또한 미국 특허청으로부터 에노보삼 병용 요법에 대한 특허 승인을 받아 2044년까지 독점적 권리를 확보했습니다.…more
$2.29+2.23%vs prev close - 8.4Pre-market26.08.04 21:30
●●●●●●●● ●●●●● ●●●●●●
베루가 세마글루타이드와 병용하는 비만 치료제 '에노보삼'의 핵심 사용 방법에 대한 미국 특허 승인 통지를 받았다. 이번 특허 확보로 2044년까지 지적재산권을 보호받게 되어 비만 치료제 시장에서의 경쟁력을 강화했다.…more
$2.29+2.23%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report